share_log

AI/ML Innovations Inc. Granted Management Cease Trade Order

AI/ML Innovations Inc. Granted Management Cease Trade Order

AI/ML創新公司被授予管理交易禁令
Accesswire ·  08/30 10:05

VICTORIA, BC / ACCESSWIRE / August 29, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, did not file its audited annual financial statements, management's discussion and analysis and related CEO and CFO certifications for the financial year ended April 30, 2024 (the "Required Filings") by the filing deadline of August 28, 2024, and as a result is in default of its obligations under Part 4 of National Instrument 51-102 Continuous Disclosure Obligations.

AI/ML Innovations Inc.(「公司」)(CSE:AIML)(OTCQB:AIMLF)(FWB:42FB)是一家致力於收購和推進人工智能/機器學習技術以解決緊迫社會需求的公司。截至2024年4月30日的財政年度,公司尚未提交審計的年度財務報表、管理層討論與分析報告以及相關CEO和CFO的認證文件(「必備文件」),違反了全國51-102號連續披露義務法規第4部分的義務。

As previously announced on August 23, 2024 (the "Announcement"), the Company applied to the British Columbia Securities Commission (the "BCSC") for a management cease trade order (the "MCTO"), which would restrict all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company. The BCSC issued the MCTO on August 29, 2024. The MCTO does not generally affect the ability of shareholders who are not insiders of the Company to trade their securities.

根據之前於2024年8月23日(「公告」)發佈的公告,公司向英屬哥倫比亞證券委員會(「BCSC」)申請進行管理停止交易令(「MCTO」),該令將限制公司的首席執行官和首席財務官(無論是直接還是間接)的所有證券交易。BCSC於2024年8月29日發佈了MCTO。MCTO通常不會影響非公司內幕人士交易其證券的能力。

The Company and its auditor continue to work diligently toward completing the Required Filings and expect to remedy the default by filing the Required Filings on or before September 15, 2024.

公司和其核數師將繼續努力完成必備文件,並預計在2024年9月15日或之前補正違約。

The Company confirms that since the date of the Announcement: (i) there has been no material change to the information set out in the Announcement that has not been generally disclosed; (ii) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the "alternative information guidelines" under National Policy 12-203 Management Cease Trade Orders ("NP 12-203") and issue bi-weekly default status reports for so long as the delay in filing the Required Filings is continuing, each of which will be issued in the form of a news release; (iii) there has not been any other specified default by the Company under NP 12-203; (iv) the Company is not subject to any insolvency proceedings; and (v) there is no material information concerning the affairs of the Company that has not been generally disclosed.

公司確認自公告發布以來:(i)未披露與公告中所提供信息不相符的任何重大變化;(ii)公司正在滿足並確認打算繼續滿足全國政策12-203號管理停止交易令(「NP 12-203」)下的「備選信息指南」的規定,併發出每兩週一次的默認狀態報告,只要必備文件的提交延遲仍在繼續,每次報告都將以新聞稿的形式發佈;(iii)公司未存在其他指定的NP 12-203違約情況;(iv)公司未處於任何破產程序;(v)沒有關於公司事務的重要未公開的信息。

For more information about AI/ML Innovations:
For detailed information please see AI/ML's website or the Company's filed documents at .

執行董事Tim Daniels:
有關詳細信息,請參見AI/ML的網站或公司在...的文件。

For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.

如需更多信息,請聯繫Blake Fallis,電話:(778)405-0882或電子郵件:info@aiml-innovations.com。

About AI/ML Innovations Inc.
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (70% owned by AIML), Tech2Heal (22% ownership commitment by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

關於人工智能/機器學習創新公司。
AI / ML 創新公司已重新調整業務運營,以利用人工智能(AI)和機器學習(ML)這兩大興旺領域的機遇,初步投資重點放在利用 AI、ML、雲計算和數字平台推動變革性醫療管理解決方案和針對全面健康的精準支持交付的新興互聯網醫療和福祉企業上。通過與 Health Gauge(AIML 70% 的所有權)、Tech2Heal(AIML 承諾持股 22%)、AI Rx Inc.(AIML 70% 的所有權)等策略性合作伙伴以及其他計劃中的增值投資,公司繼續利用擴大的增長領域,造福所有公司利益相關者。AI/ML 的股票在加拿大證券交易所上市,代碼爲「AIML」,在 OTCQb 創業公司市場上爲「AIMLF」,在法蘭克福證券交易所上市,代碼爲「42FB」。

Certain statements in this news release are "forward-looking statements", which reflect management's expectations regarding the MCTO and timing of the filing of the Required Filings. All statements other than statements of historical fact contained in this news release are forward-looking statements. Such forward-looking statements involve risks and uncertainties, as they reflect management's current beliefs and are based on information currently available to management. Actual results may differ materially from those anticipated in the statements made. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update or revise them to reflect new events or circumstances except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by the Company with the securities regulatory authorities, available at .

本新聞稿中的某些陳述屬於「前瞻性陳述」,反映了管理層對於臨時停牌令和提交所需文件的時間的預期。除本新聞稿中包含的歷史事實陳述之外,所有其他陳述都屬於前瞻性陳述。此類前瞻性陳述涉及風險和不確定性,因爲它們反映了管理層的當前信念,並基於目前管理層所掌握的信息。實際結果可能與所述陳述中預期的結果有所不同。本前瞻性陳述在其全部內容上均受到本警示性聲明的明確約束。本前瞻性陳述截至本新聞稿發佈之日起生效,公司無義務在新事件或情況發生時更新或修訂它們,除非根據適用的證券法明確要求。有關不確定性和風險的進一步信息可在公司向證券監管機構提交的披露文件中找到,具體請查詢 。

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

無論是CSE還是其監管服務提供商(如CSE政策所定義的那樣),均不對此新聞稿的充分性或準確性負責。

SOURCE: AI/ML Innovations, Inc.

來源:AI/ML創新公司,Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論